Puma Biotechnology Capital Surpluse Over Time
| PBYI Stock | USD 2.95 0.07 2.32% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Puma Biotechnology Performance and Puma Biotechnology Correlation. Puma |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Capital Surpluse Analysis
Compare Puma Biotechnology and related stocks such as Ultragenyx, Crinetics Pharmaceuticals, and Arvinas Capital Surpluse Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE | 324.1 M | 324.1 M | 324.1 M | 324.1 M | 324.1 M | 816.6 M | 1 B | 1.2 B | 1.6 B | 2.1 B | 2.8 B | 3 B | 3.1 B | 3.6 B | 2 B |
| CRNX | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 900 K | 1.2 M | 203.5 M | 203.5 M | 203.5 M | 203.5 M | 203.5 M | 234 M | 245.8 M |
| ARVN | 439.1 M | 439.1 M | 439.1 M | 439.1 M | 439.1 M | 439.1 M | 439.1 M | 439.1 M | 439.1 M | 599.1 M | 1.1 B | 1.5 B | 1.5 B | 1.8 B | 1.1 B |
| RVMD | 216 K | 216 K | 216 K | 216 K | 216 K | 216 K | 216 K | 216 K | 1.3 M | 4.7 M | 740.1 M | 1.1 B | 1.1 B | 1.2 B | 1.3 B |
| KURA | 49.5 K | 49.5 K | 49.5 K | 49.5 K | 49.5 K | 108.5 M | 110.7 M | 169.2 M | 310.8 M | 431.3 M | 913.4 M | 941.4 M | 997.1 M | 1.1 B | 1.2 B |
| TSVT | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 400 M | 607 M | 698 M | 553.9 M |
| IOVA | 14.6 M | 14.6 M | 19.1 M | 81.9 M | 121.2 M | 207.9 M | 324 M | 394.7 M | 839 M | 869.4 M | 1.5 B | 1.8 B | 1.8 B | 2.1 B | 2.2 B |
| SRPT | 341 M | 341 M | 554.9 M | 790.4 M | 1.1 B | 1.1 B | 1.5 B | 2 B | 2.6 B | 3.1 B | 3.6 B | 4.1 B | 4.1 B | 4.8 B | 5 B |
| MDGL | 413.2 M | 413.2 M | 536.3 M | 756.6 M | 756.6 M | 756.6 M | 111.7 M | 288.8 M | 616.6 M | 639.6 M | 665.4 M | 863.5 M | 1.2 B | 1.3 B | 1.4 B |
| VKTX | 54.3 M | 54.3 M | 54.3 M | 54.3 M | 54.3 M | 54.3 M | 68.3 M | 94.3 M | 401.1 M | 405.8 M | 412.6 M | 425.6 M | 445.3 M | 512.1 M | 317.3 M |
| HEPA | 17.4 M | 17.4 M | 17.4 M | 17.4 M | 17.4 M | 32.2 M | 67.5 M | 69.7 M | 76.7 M | 97.7 M | 142.9 M | 223.9 M | 223.9 M | 257.5 M | 270.4 M |
| PTCT | 465.2 M | 465.2 M | 465.2 M | 465.2 M | 820.2 M | 820.2 M | 856.1 M | 966.5 M | 1.3 B | 1.8 B | 2.2 B | 2.1 B | 2.3 B | 2.7 B | 1.6 B |
| HRTX | 174 M | 174 M | 232.4 M | 307.6 M | 378 M | 530.6 M | 564.3 M | 914 M | 1.3 B | 1.6 B | 1.6 B | 1.7 B | 1.7 B | 1.9 B | 2 B |
| CHRS | 254 M | 254 M | 254 M | 254 M | 254 M | 404.2 M | 558.5 M | 808.1 M | 946.5 M | 1 B | 1 B | 1.1 B | 1.2 B | 1.4 B | 900.6 M |
| LRMR | 349 M | 349 M | 349 M | 349 M | 349 M | 349 M | 359.3 M | 367.8 M | 444.2 M | 449.9 M | 155.3 M | 262.5 M | 262.5 M | 236.2 M | 272.9 M |
| MGNX | 254.5 M | 254.5 M | 254.5 M | 254.5 M | 335.1 M | 547.2 M | 561.2 M | 611.3 M | 732.7 M | 872.2 M | 1.1 B | 1.2 B | 1.2 B | 1.4 B | 817.2 M |
Puma Biotechnology and related stocks such as Ultragenyx, Crinetics Pharmaceuticals, and Arvinas Capital Surpluse description
My Equities
My Current Equities and Potential Positions
| Puma Biotechnology | PBYI |
| Classification | Cancer Fighters |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.95
Check out Puma Biotechnology Performance and Puma Biotechnology Correlation. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Puma Biotechnology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.